Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Kits d'Essai > Kits d'Essai ADA
Mirikizumab ELISA Kit
Mirikizumab ELISA Kit
Prix(USD) :
Spécification :
  • 96T
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueDV466018
Description
Mirikizumab ELISA Kit (DV466018) — Quantitative sandwich ELISA for Mirikizumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
  • ●Sandwich Format — High specificity, reliable quantification.
  • ●High Sensitivity — Optimized for low-abundance target detection.
  • ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillonPlasma, Serum
Sensibilité102.33 ng/ml
Plage234.38-15000 ng/ml
Numéro d'accès Q9NPF7
Applications ELISA
Méthode de détection Colorimetric
Type de test Quantitative
Retraitement 80-120%
Expédition 2-8 ℃
Stabilité et stockage The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications

Mirikizumab

Noms alternatifsLY-3074828, 1884201-71-1
Contexte

Interleukin-23 subunit alpha (Mirikizumab) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells.

1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383
2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995
3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165
4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986
5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369
6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
Note For Research Use Only.
Images
  • Mirikizumab ELISA Kit

    Standard Curve

    Standard Curve of Mirikizumab ELISA Kit

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs